Back to Search
Start Over
Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib
- Source :
- Journal of International Medical Research. 50:030006052110588
- Publication Year :
- 2022
- Publisher :
- SAGE Publications, 2022.
-
Abstract
- Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are the first-line treatment for EGFR-mutant non-small cell lung cancer. Toxicities related to EGFR-TKIs include skin rash, paronychia, and diarrhea, which in some cases can lead to dose reductions or treatment interruptions. Herein, we report the case of a 51-year-old woman affected by advanced adenocarcinoma harboring an exon 19 deletion in the EGFR gene, who was treated with second-generation EGFR-TKI following a scheduled gradual dose reduction to better manage toxicities. Following prescription labeling, treatment was initiated at a dose of 40 mg daily. After a few months, the dose was reduced to 30 mg daily owing to grade 3 skin toxicity. A metabolic complete tumor response was observed after 1 year of treatment, then therapy was continued at 20 mg daily, enabling disease stabilization. In conclusion, low dose afatinib was effective in an EGFR-mutant non-small cell lung cancer patient who required dose reductions to better manage toxicities.
- Subjects :
- Biochemistry (medical)
Cell Biology
General Medicine
Biochemistry
Subjects
Details
- ISSN :
- 14732300 and 03000605
- Volume :
- 50
- Database :
- OpenAIRE
- Journal :
- Journal of International Medical Research
- Accession number :
- edsair.doi...........7ea078deb4b1d9bb73490755428dc481